http://link.springer.de/link/service/journals/00431/contents/02/01065/
© Springer-Verlag 2002
Mark A. Fletcher1,
,
Robert Tetelboum2 and Bernard Fritzell1
| (1) | International Scientific Affairs, Wyeth Vaccines Research, Puteaux-Paris La Défense, France |
| (2) | Medical Department, Wyeth, France |
Abstract. The French decision-making processes for recommendation and introduction of infant vaccination with Prevenar reflect a public health-based dialogue between the Direction Générale de la Santé and Wyeth (Paris-La Défense, France) nurtured by open and ongoing exchanges. Three surveillance programmes are being discussed: (1) to ascertain the future impact of large-scale Prevenar vaccination on invasive pneumococcal disease incidence, (2) to follow the evolution and carriage of pneumococcus and (3) to look at the possibilities to establish an epidemiological surveillance and active "vaccinovigilance" in France (to estimate the number of adverse events that might be expected among the population targeted by the vaccination recommendation). Conclusion: in this way, the Direction Générale de la Santé and Wyeth are working towards the implementation of a broad-scale vaccine introduction.
Keywords. Child - Conjugate vaccines - France - Pneumococcal infections - Streptococcus pneumoniae
Abbreviations. CSHPF Conseil Supérieur d'Hygiène Publique de France DGS Direction Générale de la Santé IPD invasive pneumococcal disease
|
|
E-mail:
fletchm@wyeth.com Phone: +33-1-41027959 Fax: +33-1-41027534 |
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.